Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study

Netto, Lucas Chaves; Ibrahim, Karim Yaqub; Picone, Camila de Melo; Alves, Ana Paula P S; Aniceto, Eliane Vieira; Santiago, Mariana Rodrigues; Parmejani, Patrícia S S; Aikawa, Nádia E.; Medeiros-Ribeiro, Ana Cristina; Pasoto, Sandra Gofinet; Yuki, Emily Figueiredo Neves; Saad, Carla G. S.; Pedrosa, Tatiana do Nascimento; Lara, Amanda Nazareth; Ceneviva, Carina; Bonfá, Eloísa; Kallás, Esper G.; Avelino‐Silva, Vivian Iida

doi:10.1016/s2352-3018(22)00033-9

Cited by 41 publications

(82 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Within a cohort of 166 PLWH who received an mRNA-based vaccine, those with CD4 + T-cell counts < 200 cells/µL had reduced humoral and T-cell immunity compared to those with CD4 + T-cell counts > 500 cells/µL [65]. PLWH who received the Novavax vaccine had attenuated humoral immune responses [66] as did those who received Coro-naVac [67]. A cohort 136 PLWH who received mRNA vaccination demonstrated comparable humoral and cellular responses, although those with CD4 + counts < 300 cells/µL had lower binding antibodies [68].…”

Section: Protection From Sars-cov-2 Vaccinationmentioning

confidence: 99%

COVID-19 Outcomes and Risk Factors Among People Living with HIV

2022

View full text Add to dashboard Cite

Purpose of Review In this review, we examine the intersection of the HIV and COVID-19 epidemics with focus on COVID-19-related health outcomes and risk factors for SARS-CoV-2 among people living with HIV (PLWH). Recent Findings Evidence to date do not suggest a higher incidence of SARS-CoV-2 infection among PLWH compared to the general population, although—once exposed—PLWH are at greater risk of severe COVID-19 outcomes. Key risk factors for severe COVID-19 include non-HIV comorbidities known to be associated with severe disease, as well as HIV-specific risk factors such as low CD4 + T-cell count, unsuppressed viral load, and tuberculosis co-infection. The disproportionate impact of the SARS-CoV-2 pandemic among Black, Latinx, and Native American/Alaskan Native PLWH could worsen pre-existing disparities in health outcomes among PLWH. Data on SARS-CoV-2 vaccine protection among PLWH needs additional study, although some studies suggest decreased humoral responses among those with low CD4 + T-cell counts, while there is a signal of increased vaccine breakthrough rates among PLWH in two large observational cohorts. Data on post-acute sequelae of SARS-CoV-2 (PASC) among PLWH is also limited. Summary PLWH do not have a higher susceptibility to SARS-CoV-2, but once exposed, they are at higher risk of severe COVID-19 outcomes. Additional resources will need to be dedicated to the development of interventions to improve health outcomes and address disparities among PLWH impacted by the COVID-19 pandemic.

show abstract

Section: Protection From Sars-cov-2 Vaccinationmentioning

confidence: 99%

COVID-19 Outcomes and Risk Factors Among People Living with HIV

2022

View full text Add to dashboard Cite

show abstract

“…In one study, Lucas Netto and colleagues studied people living with HIV at the University of Sao Paulo, Brazil. 2 They compared CoronaVac immunogenicity responses in people living with HIV with CD4 counts less than 500 cells per μL with people living with HIV with CD4 counts of 500 cells per μL or more. Immunogenicity was reduced in those with CD4 counts less than 500 cells per μL, suggesting that these individuals could be at increased risk of an inadequate antibody response to vaccines.…”

mentioning

confidence: 99%

HIV and COVID-19: juxtaposition of two pandemics

Nkengasong¹

2022

The Lancet HIV

View full text Add to dashboard Cite

“…For example, some subtypes of cancer may have great impact on the immune system, resulting in an abnormal response to the vaccination. However, the assessment for safety and immunogenicity of CoronaVac on HIV positive or autoimmune rheumatic diseases (ARD) patients showed that the immunogenicity of immunosuppressed patients was significantly decreased, but remained within an acceptable range; and they all showed a good safety profile with the CoronaVac vaccines 29,30 . Therefore, we believe that CoronaVac will be safe in immune-related cancers but requires further efficacy and safety evaluation to provide precise vaccination guidance.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: People living with chronic disease, particularly seniors older than 60 years old, are lagging behind in the national vaccination campaign in China due to uncertainty of safety and effectiveness. However, this special population made up of most severe symptom and death cases among infected patients and should be prioritized in vaccination program. In this retrospective study, we assessed the safety and immunogenicity of the CoronaVac inactivated vaccines in people with underlying medical conditions to address the vaccine hesitation in this special population. Methods: In this cohort study, volunteers aged 40 years and older, had received two doses of CoronaVac inactivated vaccines (3-5 weeks interval), been healthy or with at least one of the six diseases: coronary heart disease (CAD), hypertension, diabetes mellitus (DM), chronic respiratory disease (CRD), obesity and cancer, were recruited from 4 study sites in China. The primary safety outcome was the incidence of adverse events within 14 days after each dose of vaccination. The primary immunogenic outcome was geometric mean titer (GMT) of neutralizing antibodies to living SARS-CoV-2 virus at 14-28 days, 3 months, and 6 months after full two-dose vaccination. This study is registered with ChiCTR.org.cn (ChiCTR2200058281) and is active but no longer recruiting. Findings: Among 1,302 volunteers screened between Jul 5 and Dec 30, 2021, 969 were eligible and enrolled in our cohort, including 740 living with underlying medical conditions and 229 as healthy control. All of them formed the safety cohort. The overall incidence of adverse reactions was 150 (20.27%) of 740 in the comorbidities group versus 32 (13.97%) of 229 in the healthy group, with significant difference (P=0.0334). The difference was mainly contributed by fatigue and injection-site pain in some groups. Most adverse reactions were mild (Grade 1). We did not observe any serious adverse events related to vaccination. By day 14-28 post vaccination, the seroconversion rates and GMT of neutralizing antibody showed no significant difference between disease group and healthy group, except CAD group (P=0.03) and CRD group (P=0.04) showed slight reduction. By day 90, the neutralizing antibody GMTs were significantly reduced in each group, with no significant difference between diseases and healthy group. By day 180, the neutralizing antibody continued to decrease in each group, but with slower declination. Interpretation: For people living with chronic disease especially seniors older than 60 years, the CoronaVac vaccines are as safe as in healthy people. Although the immunogenicity is slightly different in subgroup of some diseases compared with that of the healthy population, the overall trend was consistent. Our findings highlight the evidence to address vaccine hesitancy for seniors and people living with chronic diseases. Funding: Yunnan Provincial Science and Technology Department (202102AA100051 and 202003AC100010, China), Sinovac Biotech Ltd (PRO-nCOV-4004).

show abstract

Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study

Cited by 41 publications

References 36 publications

COVID-19 Outcomes and Risk Factors Among People Living with HIV

COVID-19 Outcomes and Risk Factors Among People Living with HIV

HIV and COVID-19: juxtaposition of two pandemics

Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study

Contact Info

Product

Resources

About